AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Diagnostic Kit Claims 100% Detection.(Hiso-RECAF diagnostic kit for detection of breast cancer from BioCurex, Inc.)
2001 JUL 5 - (NewsRx Network) -- BioCurex, Inc. (OTC:BOCX) announced the first results on use of its Hiso-RECAF diagnostic kit for detection of breast cancer.
Dr. G. Ardao. chief of the department of pathology and Dr. G. Gualco of Montevideo. Uruguay. reviewed a significant number of breast tissue samples selected at random. The samples included malignant, benign (fibroadenomas), and dysplastic (benign diffuse growth) specimens. They reported 100% detection of breast cancer with no false positives among the dysplasias and the benign tumors. Furthermore, several in-situ carcinomas were strongly positive.
A gradient of the intensity of the staining was noticed, from very strong in the malignant cells to almost negative in the benign/normal cells at the periphery of the malignant lesions, thus suggesting a relationship between the expression of RECAF and the degree of malignancy. The results strongly supported BioCurex's technology and validated its core RECAF receptor as a cancer marker for breast tissue. Presently. no other marker provides this level of detection for breast cancer.
The RECAF cancer marker is ...
- Genentech and DAKO Announce Collaboration On HER2 Diagnostic Kit in Breast...
- Press release article from: Business Wire March 2, 1998 700+ words
...will develop an in vitro diagnostic kit to be used to screen breast cancer patients for overexpression...overexpressing metastatic breast cancer," said Susan Hellmann...this aggressive form of breast cancer who may be eligible for...
- A&G Pharmaceutical Completes $750,000 Private Financing; - Funding Will Support...
- Press release article from: PR Newswire March 24, 2004 700+ words
...on the Company's serum diagnostic kit for breast cancer. A&G is developing...monitoring cancer recurrence in breast cancer patients. ABOUT A&...diagnosis, and treatment of breast cancer. The Company has established...
- Nexell Therapeutics Cytonex In Vitro Diagnostic Kit Poised to Play Greater Role...
- Press release article from: Business Wire March 1, 2000 700+ words
...bone marrow of breast cancer patients and...samples from breast cancer patients at...first in vitro diagnostic kit, the Cytonex...Class I-exempt diagnostic kit on the U.S...the marrow of breast cancer patients is...
- FDA Approves BioGenex InSite(TM) Her-2/neu Kit; Kit Aids in Breast Cancer...
- Press release article from: PR Newswire February 3, 2005 700+ words
...neu Kit. This in vitro diagnostic kit is used to identify breast cancer patients eligible for...immunohistochemistry (IHC) staining of breast cancer tissue. The automated...including a complete panel for breast cancer with additional FDA cleared...
- BioCurex (Rancho Santa Margarita, California).(receives Canadian marketing...
- Newspaper article from: Diagnostics & Imaging Update November 1, 2001 700+ words
...Canadian approval for its flagship product, the Histo-RECAF diagnostic kit for the detection of cancers of breast, lung, stomach...BioCurex's technology is based, is used in detecting breast cancer and also is present in all malignant tissues studied to...
- Samaritan Breast Cancer Diagnostic Issued U.S. Patent.
- Press release article from: M2 Presswire May 15, 2007 700+ words
...Afternoon Movers: Samaritan Breast Cancer Diagnostic Issued U.S. Patent...09/047,652. Samaritan's diagnostic kit is comprised of antibodies against...the presence of an aggressive breast cancer tumor. This patent's claims...
- AMDL Announces MyGene Granted Distribution Rights for DR-70(R) Cancer...
- Press release article from: PR Newswire March 31, 2003 700+ words
...virus for cervical cancer, as well as BRC1 and BRC2 for breast cancer. "MyGene is well respected throughout the South Korean...contracted with the University of Florida to begin studies of breast cancer using the combination immunogene therapy technology. More...
- MyGene, Inc. Says it Wins Government Approval to Market AMDL's DR-70(R) Cancer...
- Press release article from: PR Newswire January 22, 2007 700+ words
...people, and currently markets a unique test for human papilloma virus for cervical cancer, as well as BRC1 and BRC2 for breast cancer. "MyGene is well respected throughout the South Korean medical community," said Gary L. Dreher, AMDL CEO. "South...